Related Experiment Videos
Interleukin 10 reduces mortality from severe peritonitis in mice
Antimicrobial Agents and Chemotherapy
|June 1, 1995
Summary
Interleukin 10 (IL-10) therapy administered after sepsis induction significantly improved survival rates in mice. This cytokine modulation shows potential for treating sepsis and related organ failure by suppressing inflammatory tumor necrosis factor (TNF).
Area of Science:
- Immunology
- Sepsis Pathophysiology
- Cytokine Signaling
Background:
- Interleukin 10 (IL-10) is an anti-inflammatory cytokine that suppresses proinflammatory cytokines like tumor necrosis factor (TNF) and IL-1.
- Monocytes and macrophages induce IL-10 during sepsis, suggesting a role in the immune response to infection.
Purpose of the Study:
- To evaluate the therapeutic efficacy of IL-10 in improving survival rates in a murine model of sepsis.
- To investigate the impact of IL-10 administration timing on its therapeutic effect.
Main Methods:
- Utilized the murine cecal ligation-and-puncture (CLP) model to induce sepsis.
- Administered recombinant murine IL-10 at varying doses and time points relative to CLP induction.
- Measured survival rates and circulating TNF levels in septic mice.
Main Results:
- Administration of 1 microgram or more of IL-10, 6 hours after CLP induction, significantly decreased lethality in septic mice.
- IL-10 treatment post-sepsis induction suppressed the elevation of circulating TNF.
- IL-10 administration simultaneously or 6 hours before CLP induction did not affect survival rates.
- Anti-TNF antibody treatment after CLP induction showed no effect on survival.
Conclusions:
- Timing of IL-10 administration is critical for therapeutic efficacy in sepsis.
- IL-10 demonstrates potential as a therapeutic agent for sepsis and sepsis-related multiple organ failure.
- Cytokine modulation with IL-10 offers a promising strategy for managing sepsis complications.